Stock Research: ANI Pharma

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

ANI Pharma

NMQ:ANIP US00182C1036
97
  • Value
    100
  • Growth
    93
  • Safety
    Safety
    51
  • Combined
    97
  • Sentiment
    87
  • 360° View
    360° View
    97
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANI Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and commercializes therapeutics. It operates in the biopharmaceutical industry, with a focus on rare disease conditions and branded pharmaceutical products. The company's operations are primarily within the United States. In the last fiscal year, the company had a market cap of $1,379 million, profits of $364 million, and revenue of $614 million, with 897 employees.

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
100 53 42 61
Growth
93 59 79 85
Safety
Safety
51 69 55 36
Sentiment
87 80 96 34
360° View
360° View
97 88 93 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
67 83 76 17
Opinions Change
50 50 83 92
Pro Holdings
n/a 36 74 49
Market Pulse
70 91 48 30
Sentiment
87 80 96 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
100 53 42 61
Growth
93 59 79 85
Safety Safety
51 69 55 36
Combined
97 76 73 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
84 55 44 56
Price vs. Earnings (P/E)
70 70 68 87
Price vs. Book (P/B)
65 42 39 46
Dividend Yield
98 1 1 1
Value
100 53 42 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
60 83 41 77
Profit Growth
87 53 98 35
Capital Growth
77 30 37 59
Stock Returns
61 49 77 91
Growth
93 59 79 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
21 47 38 40
Refinancing
53 63 77 41
Liquidity
62 57 40 44
Safety Safety
51 69 55 36

Similar Stocks

Discover high‑ranked alternatives to ANI Pharma and broaden your portfolio horizons.

Salesforce

NYQ:CRM
Country: USA
Industry: Application Software
Size: XX-Large
Full Stock Analysis

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

Walt Disney

NYQ:DIS
Country: USA
Industry: Movies & Entertainment
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NSQ:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is a high-quality, high-growth stock with positive sentiment. However, the financing is on the riskier side. It is best for a growth-focused investor willing to accept higher financial risk for potentially higher shareholder returns.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: